Syantra
syantra.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$4.9M
1 round on record
Latest round
$4.9M
Series A · Sep 2024 · 2 yr ago
Backers
2
Plug and Play, Thin Air Labs
The money's age
Long since its last round
25 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 11, 2024
Raised a round Series A $4.9M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Sep 2024 | $4.9M | — | menafn.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Plug and Play 
Thin Air Labs Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Advesya is transforming the fight against cancer and autoimmune diseases. Building on years of academic research, advesya’s innovative work…
Meet EXOKĒRYX™ Powering EV research to realize earlier disease detection. We're speeding up the fight against cancer and other diseases by…
Glycan excellence against cancer. About us.
The world's first cancer protection system. When you're healthy, Need continually analyzes your data to help prevent and detect cancer…
C the Signs is an MHRA Class I medical device helping GPs detect and refer patients at risk of cancer earlier, when survival is highest.
Transforming Cancer Detection Through miRNA Technology. Early diagnosis and early treatment response monitoring save lives and improve…
News
Syantra, Inc., announces new therapeutic division for immuno-oncology drug discovery, leveraging its patent-pending Onco-ID platform
Syantra, Inc., a biotechnology company revolutionizing cancer detection, today announced a new therapeutic division that will focus on developing first-in-class therapies to help reverse cancer-related immune cell corruption and restore anti-cancer immuni
Read more
Report
Syantra Inc completes new IP filings in cancer screening and treatment
Syantra, Inc., has recently completed new patent filings that expand previous work in cancer molecular diagnostics to encompass new drug targets and therapeutics.
Read more
Report
Syantra, Inc. Welcomes STEM Advocate and Breast Cancer Conqueror Holly Smithson to Its Board of Directors
Syantra, Inc., a precision biotechnology company revolutionizing cancer detection and treatment, proudly announces the appointment of Holly Smithson to its Board of Directors.
Read more
Report
Syantra Secures $4.9 Million in Series A-1 Funding; Adds Dr. Rick Mangat to Board of Directors
/PRNewswire/ - Syantra, Inc., a privately held precision biotechnology company pioneering a platform to change the way cancer is detected and treated,...
Read more
Report
Syantra Secures $4.9 Million In Series A-1 Funding Adds Dr. Rick Mangat To Board Of Directors
Read more
Report
UCalgary biomedical engineering project receives funding for joint breast cancer detection research
U.S. government grant supports international research partnership with Cornell University
Read more
Report
Syantra Announces Liquid Biopsy Platform Breakthrough with Expanded Intellectual Property Portfolio; Partnership with Limmi to Accelerate AI-Powered RNA-Based Early Cancer Detection Liquid Biopsy Program
/PRNewswire/ - Today, Syantra, a liquid biopsy platform and innovation company that is changing the way cancer is detected, starting with Syantra DXTM Breast...
Read more
Report
Frontiers Linking Aortic Mechanical Properties, Gene Expression and Microstructure: A New Perspective on Regional Weakening in Abdominal Aortic Aneurysms
Background: Current clinical practice for the assessment of abdominal aortic aneurysms (AAA) is based on vessel diameter and does not account for the multifa...
Read more
Report
Report
Report
Show more news
Financials
Total raised
$4.9M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2024 | $4.9M | Details |